Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | MC5R | P33032 | 1/20 | 0.68 |
| ▸ | MC3R | P41968 | 1/20 | 0.68 |
| ▸ | MC1R | Q01726 | 1/20 | 0.68 |
| ▸ | G6PD | P11413 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | MPO | P05164 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | HTR1D | P28221 | 1/20 | 0.61 |
| ▸ | HTR1B | P28222 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17232881 | 0.85 | MC5R (0.83) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL7970552 | 0.84 | MC5R (0.81) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL4985934 | 0.82 | HTR2A (0.77) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL379409 | 0.82 | HTR2A (1.00) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL106450 | 0.82 | HTR2A (0.70) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL29385251 | 0.82 | HTR2A (1.00) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL3377341 | 0.82 | HTR2A (0.70) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL10923944 | 0.82 | HTR2A (0.70) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL10089577 | 0.82 | HTR2A (0.70) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL3377723 | 0.82 | HTR2A (0.70) | HTR2AKDM4EALDH1A1HTR1AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107400128-B | Monoterpene-like indole alkaloid and preparation method and application thereof | 贵州省中国科学院天然产物化学重点实验室 | 2020-03-31 | — | — | CN | claimed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | claimed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | claimed |
| CN-107400128-B | Monoterpene-like indole alkaloid and preparation method and application thereof | 贵州省中国科学院天然产物化学重点实验室 | 2020-03-31 | — | — | CN | disclosed |
| EP-2099442-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008082856-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | HTR2A 2945/4885KDM4E 418/4885ALDH1A1 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.